Methylphenidate for Children and Adolescents with ADHD – unpublished trials

Corresponding Author: Magnus Tang Kristensen. Psychiatric Research Unit. Region Zealand. Denmark. magkri@regionsjaelland.dk

Other Authors: Ole Jakob Storebø. Psychiatric Research Unit. Region Zealand. Denmark.

Christian Gluud. Copenhagen Trial Unit. Rigshospitalet. Denmark

Abstract

Introduction

This is a follow-up study on a recent systematic review by Storebø et al. [1]. It aims to investigate research waste and publication bias in randomized clinical studies investigating the use of methylphenidate for children and adolescent with ADHD.

Method

The method used includes an initial cohort selection from searching Clinicaltrials.gov and the EUCTR with the following inclusion criteria: Use of methylphenidate either as stand-alone or part of psychological treatment for ADHD, randomised clinical trials, any dosage, any delivery method and at least 75% children and adolescents with ages less than 18.

Results

The primary objective is to assess how many randomised clinical trials of methylphenidate on children and adolescents with ADHD are registered in protocol databases, but never published in academic literature or as tabular summary results. The number of participants included in these trials is a secondary objective.

The tertiary objective is to assess the time from registry to publication of randomised clinical trials of methylphenidate on children and adolescents with ADHD in either a journal or as summary results, and the number of participants in these trials. The cutoff time for a publication to be considered timely published will be 12 months, as per FDAA guidelines [3]

Background

This is a follow-up study on a recent systematic review by Storebø et al. [1]. This review suggested potential benefits of methylphenidate on ADHD core symptom severity as well as general behavior, but the certainty of the evidence for the use of methylphenidate for ADHD in children and adolescent was found to be low in all 212 randomised clinical trials [1]. Furthermore, most trials were quite small, with the average sample size being 70 children. This calls into question small trial effects and publication bias, which is commonly analyzed via funnel plots. The review of Storebø et al. identified bias, but not significant publication bias [1]. Egger's regression intercept was −0.2260 (two-tailed, p=0.81). Small trials have a higher variance, which can give misleading data if only the desired results are published, such that only one part of the variance is made public. This part depends on if the measured effect is beneficial or harmful.

Methylphenidate has been used globally for more than 60 years for treatment of children with ADHD [1]. Methylphenidate is related to dopaminergic and noradrenergic neurotransmissions in the brain [1]. Methylphenidate can be delivered via immediate, sustained, or extended release. Furthermore, it can be oral or transdermal [1]. The dosage of methylphenidate can vary significantly. The dose can range from 5 mg to 60 mg of methylphenidate per day, 1.4 mg/kg daily administered in two or three doses [1].

Research waste and late publishing of studies is an area that has received increased focus as of late [2]. A recent German study of University Medical Centers found that prospective registration had increased from 33% to 75% between 2009 and 2017 for trials registered in ClinicalTrials.gov. However, only 41% of included trials had published their result within 2 years of trial completion and 31% had not published their result even after 5 years [2].

The German study used 24 months after registration of the protocol as their trial completion date. The 2007 Food and Drug Administration Amendments Act (FDAA) has, however, required sponsors of certain clinical trials to make tabular summary results publicly available on ClinicalTrials.gov within 12 months of a trials primary completion date [3].

Objectives

The primary objective is to assess how many randomised clinical trials of methylphenidate on children and adolescents with ADHD are registered in protocol databases, but never published in academic literature or as tabular summary results. The number of participants included in these trials is a secondary objective.

The tertiary objective is to assess the time from registry to publication of randomised clinical trials of methylphenidate on children and adolescents with ADHD in either a journal or as summary results, and the number of participants in these trials.

Research questions

How many randomised clinical trials on methylphenidate for children and adolescents with ADHD are registered as protocols of completed and terminated trials in clinical trial registers, but never published as articles in the academic literature? To what extent do the trials registered in clinical trial registers follow the 12 month deadline for publication of tabular summary results after the primary completion date?

Methodology

1. Cohort selection

A search for trial registers for studies with methylphenidate is made with the following inclusion criteria:

- Use of methylphenidate either as stand-alone or part of psychological treatment for ADHD
- Randomised clinical trials
- Any dosage
- Any delivery method
- At least 75% children and adolescents with ages less than 18.

We will search ClinicalTrials.gov and EUCTR

The search string used for ClinicalTrials.gov is the following:

Advanced search. Conditon or disease: ADHD. Other terms: Methylphenidate. Study Type: Intervention Studies. Age group: Child(Birth to 17).

The search string used for EUCTR was the following:

Advanced search. Search ADHD AND methylphenidate. Choose Under 18.

Both search strings used filters for studies under 18. This differs from Storebø 2023, however when including studies with 18 year olds the amount of search results did not change, so the filters where used for easier searching.

Method for literature search and validation of findings was inspired by Bruckner T & Grzegorzek [4]

2. First literature search

Of the included cohort, the following steps will be taken:

- Scan for tabular summary results
- Scan for publications uploaded by sponsor/investigator or automatically indexed by registry
- Enter clinical trial identifier in Google Scholar and search first 2 pages for potential match by title.
- Enter clinical trial identifier in Google Scholar and search first 2 pages for potential match by putting the principal investigator name in “quotations”.

If, at any step, a publication is found, it will be verified that it is a results publication and not just another registry protocol or other irrelevant document. Judgement will be made via title and abstract. Full text only if needed. The date and link to publication will be extracted.

If the trial publication does not include the result of the primary outcome, then the search will continue. Grey literature such as posters or presentation slides will be extracted separately in a spreadsheet.

3. Validation of findings

First, Storebø et al 2023 [1] will be referenced to see if a trial publication was found in the previous data collection, either as included or excluded

An email to the company or institution that sponsored the trial will be sent, with one reminder email if no response. Emails will disclose that the study in question is to be used in a study on research waste.

An email to the company or institution that sponsored a trial with no results could be found will be sent and invite the sponsor to either send any relevant publications that were missed or provide a short on-the-record statement on their clinical reporting policies and plans for inclusion in a supplementary annex of the final manuscript.

4. Second literature search

A second search will be made for clinical trials where first search returned unsuccessful and the sponsor did not provide the status of the trial

- First, a repeat of the first steps will be made
- Then, PubMed will be searched with the clinical trial identifier
- PubMed will be searched for +”intervention name” and +”condition name”. The first 2 pages will be searched
- Google Scholar will be searched for +”intervention name” and +”condition name”. The first 2 pages will be searched

Outcomes

The first outcome is the extent of publications of randomised clinical trials of methylphenidate for children and adolescents with ADHD in a peer-reviewed journal or PhD thesis for trials missing summary results in clinical trial databases

The second outcome is the speed of publication for randomised clinical trials of methylphenidate on children and adolescents with ADHD in a peer-reviewed journal or PhD thesis for trials registered in clinical trial databases

The speed is calculated by the time difference between a trial's primary completions date and the first published date of the trial in a peer-reviewed journal and/or a registry.

Summary statistics

Three tables will be made regarding publication speed and research waste as a % of trials, % of patients, # of patients and # of trials.

Table 1: Publication speed and research waste of randomised clinical trials on methylphenidate for children and adolescent with ADHD, % of trials

	Timely publication	Delayed publication			Research waste	Publication speed (average months)
	Within 1 year	Within 1-2 years	Within 2-3 years	After 3 years	No results	
All Trials						

Table 2: Publication speed and research waste of randomised clinical trials of methylphenidate in children and adolescent with ADHD, # of trials

	Trials total	Timely publication	Delayed publication			Research Waste
		Within 1 year	Within 1-2 years	Within 2-3 years	After 3 years	No results
All Trials						

Table 3: Publication speed and research waste of randomised clinical trials on methylphenidate for children and adolescent with ADHD, % of patients

	% of patients	Timely publication	Delayed publication			Research waste
		Within 1 year	Within 1-2years	Within 2-3 years	After 3 years	No results
All Trials						

Table 4: Publication speed and research waste of randomised clinical trials on methylphenidate for children and adolescent with ADHD, # of patients

	Patients total	Timely publication	Delayed publication			Research waste
		Within 1 year	Within 1-2 years	Within 2-3 years	After 3 years	No results
All Trials						

A Kaplan-Meier curve tracking publication speed will also be included.

References:

1. Storebø OJ, Storm MR, Pereira Ribeiro J, Skoog M, Groth C, Callesen HE, et al (2023). Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews 2023, Issue 3. Art. No.: CD009885. DOI: 10.1002/14651858.CD009885.pub3. Accessed 29 March 2023.

2. Franzen DL, Carlisle BG, Salholz-Hillel M, Riedel N, Strech D (2023) Institutional dashboards on clinical trial transparency for University Medical Centers: A case study. PLoS Med 20(3): e1004175. https://doi.org/10.1371/journal.pmed.1004175

3. 2008 FDAA Section 801 clinicaltrails.gov/ct2/manage-recs/fdaaa

4. Bruckner T, Grzegorzek D (2022) *Are Metastatic Breast Cancer Clinical Trials in Germany Reporting Results in Accordance with the WHO Joint Statement? – Protocol for a Mixed Methods Study.* TranspariMED.